Estimated population-level impact of using a six-week regimen of daily rifapentine to treat latent tuberculosis infection in the United States

Sourya Shrestha; Andrea Parriott; Nicolas A. Menzies; Priya B. Shete; Andrew N. Hill; Suzanne M. Marks; David W. Dowdy

doi:10.1513/AnnalsATS.202005-574RL

Estimated population-level impact of using a six-week regimen of daily rifapentine to treat latent tuberculosis infection in the United States

Sourya Shrestha, Andrea Parriott, Nicolas A. Menzies, Priya B. Shete, Andrew N. Hill, Suzanne M. Marks, David W. Dowdy

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1639-1642
Number of pages	4
Journal	Annals of the American Thoracic Society
Volume	17
Issue number	12
DOIs	https://doi.org/10.1513/AnnalsATS.202005-574RL
State	Published - Dec 2020

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1513/AnnalsATS.202005-574RL

Cite this

@article{4f3f8b138e65417b9e856cd2615ca303,

title = "Estimated population-level impact of using a six-week regimen of daily rifapentine to treat latent tuberculosis infection in the United States",

author = "Sourya Shrestha and Andrea Parriott and Menzies, {Nicolas A.} and Shete, {Priya B.} and Hill, {Andrew N.} and Marks, {Suzanne M.} and Dowdy, {David W.}",

note = "Funding Information: Supported by the Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (#5U38PS004649, #1U38PS004644, #5U38PS004649). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or other authors' affiliated institutions.",

year = "2020",

month = dec,

doi = "10.1513/AnnalsATS.202005-574RL",

language = "English (US)",

volume = "17",

pages = "1639--1642",

journal = "Annals of the American Thoracic Society",

issn = "2329-6933",

publisher = "American Thoracic Society",

number = "12",

}

TY - JOUR

T1 - Estimated population-level impact of using a six-week regimen of daily rifapentine to treat latent tuberculosis infection in the United States

AU - Shrestha, Sourya

AU - Parriott, Andrea

AU - Menzies, Nicolas A.

AU - Shete, Priya B.

AU - Hill, Andrew N.

AU - Marks, Suzanne M.

AU - Dowdy, David W.

N1 - Funding Information: Supported by the Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (#5U38PS004649, #1U38PS004644, #5U38PS004649). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or other authors' affiliated institutions.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85097112348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097112348&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.202005-574RL

DO - 10.1513/AnnalsATS.202005-574RL

M3 - Letter

C2 - 32916062

AN - SCOPUS:85097112348

SN - 2329-6933

VL - 17

SP - 1639

EP - 1642

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

IS - 12

ER -

Estimated population-level impact of using a six-week regimen of daily rifapentine to treat latent tuberculosis infection in the United States

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this